Citations

Mayo Clinic

Showing 10 of 108602 citations.

Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Raleigh, David R. , Youngblood, Mark W. , Polley, Mei‐Yin C. , Mirchia, Kanish , Won, Minhee , Harmanci, Arif , Vasudevan, Harish N. , Yu, Theresa, Bhave, Varun , Lam, Tai‐Chung , Pu, Jenny Kan-Suen, Chang, Jason Y. , Haberler, Christine , Mawrin, Christian , Rood, Brian , Chew, Jessica, Boreta, Lauren , Butowski, Nicholas , Bush, Nancy Ann Oberheim , Chandler, James P. , Rogers, Leland , Pugh, Stephanie L. , Sneed, Penny K. , Raleigh, David , Choudhury, Abrar , Youngblood, Mark , Leung, Gilberto , Palmer, Joshua D , Berghoff, Anna , Preusser, Matthias , Santagata, Sandro , Solomon, David A , Horbinski, Craig , Perry, Arie , Sahm, Felix , Chen, William C. , Lucas, Calixto‐Hope G. , Maas, Sybren L. N. , Suwala, Abigail Kora , Bayley, James C. , Harmancı, Akdes Serin , Klisch, Tiemo Jürgen , Nguyen, Minh , McCortney, Kathleen , Perlow, Haley K. , Palmer, Joshua D. , Preusser, Matthias , Nicolaides, Theodore , Agnihotri, Sameer , Resnick, Adam , Young, Jacob S. , Braunstein, Steve , Schulte, Jessica D. , Spetzler, David B. , Villanueva-Meyer, Javier E. , Solomon, David A. , Mehta, Minesh P. , Berger, Mitchel S. , Horbinski, Craig , McDermott, Michael , Perry, Arie , Bi, Wenya Linda , Patel, Akash J. , Sahm, Felix , Magill, Stephen T.

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2663611/v1 | PMID 36993741 Get It

Abstract Background Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and current indications for postoperative radiotherapy are controversial. Recent studies have proposed prognostic meningioma classification systems using DNA methylation profiling, copy number variants, DNA sequencing, RNA sequencing, histology, or integrated models based on multiple combined features. Targeted gene expression profiling has generated robust biomarkers integrating multiple molecular features for other cancers, but is understudied for meningiomas. Methods Targeted gene expression profiling was performed on 173 meningiomas and an optimized gene expression biomarker (34 genes) and risk score (0 to 1) was developed to predict clinical outcomes. Clinical and analytical validation was performed on independent meningiomas from 12 institutions across 3 continents (N = 1856), including 103 meningiomas from a prospective clinical trial. Gene expression biomarker performance was compared to 9 other classification systems. Results The gene expression biomarker improved discrimination of postoperative meningioma outcomes compared to all other classification systems tested in the independent clinical validation cohort for local recurrence (5-year area under the curve [AUC] 0.81) and overall survival (5-year AUC 0.80). The increase in area under the curve compared to the current standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval [CI] 0.07–0.17, P < 0.001). The gene expression biomarker identified meningiomas benefiting from postoperative radiotherapy (hazard ratio 0.54, 95% CI 0.37–0.78, P = 0.0001) and re-classified up to 52.0% meningiomas compared to conventional clinical criteria, suggesting postoperative management could be refined for 29.8% of patients. Conclusions A targeted gene expression biomarker improves discrimination of meningioma outcomes compared to recent classification systems and predicts postoperative radiotherapy responses.
Real‐time quaking‐induced conversion assays for prions: Applying a sensitive but imperfect test in clinical practice
Jones, Samuel, Lazar, Evelyn, Porter, Amanda , Prusinski, Christian , Brier, Matthew R. , Bucelli, Robert C. , Day, Gregory S. , Jones, Samuel M, Lazar, Evelyn B, Porter, Amanda L, Prusinski, Christian C , Day, Gregory S

European Journal of Neurology | March 20, 2023 | Volume: 30 | Issue: 7 | Pages: 1854-1860

10.1111/ene.15795 | PMID 36940265 Get It

AbstractBackground and purposeReal‐time quaking‐induced conversion (RT‐QuIC) assays offer a sensitive and specific means for detection of prions, although false negative results are recognized in clinical practice. We profile the clinical, laboratory, and pathologic features associated with false negative RT‐QuIC assays and extend these to frame the diagnostic approach to patients with suspected prion disease.MethodsA total of 113 patients with probable or definite prion disease were assessed at Mayo Clinic (Rochester, MN; Jacksonville, FL; Scottsdale, AZ) or Washington University School of Medicine (Saint Louis, MO) from 2013 to 2021. RT‐QuIC testing for prions was performed in cerebrospinal fluid (CSF) at the National Prion Disease Pathology Surveillance Center (Cleveland, OH).ResultsInitial RT‐QuIC testing was negative in 13 of 113 patients (sensitivity = 88.5%). RT‐QuIC negative patients were younger (median = 52.0 years vs. 66.1 years, p < 0.001). Other demographic and presenting features, and CSF cell count, protein, and glucose levels were similar in RT‐QuIC negative and positive patients. Frequency of 14‐3‐3 positivity (4/13 vs. 77/94, p < 0.001) and median CSF total tau levels were lower in RT‐QuIC negative patients (2517 vs. 4001 pg/mL, p = 0.020), and time from symptom onset to first presentation (153 vs. 47 days, p = 0.001) and symptomatic duration (710 vs. 148 days, p = 0.001) were longer.ConclusionsRT‐QuIC is a sensitive yet imperfect measure necessitating incorporation of other test results when evaluating patients with suspected prion disease. Patients with negative RT‐QuIC had lower markers of neuronal damage (CSF total tau and protein 14‐3‐3) and longer symptomatic duration of disease, suggesting that false negative RT‐QuIC testing associates with a more indolent course.
Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training
Bali, Aman S. , Picco, Michael F., Kinnucan, Jami , Kinnucan, Jami A., Bali, Aman , Hashash, Jana G. , Farraye, Francis A.

American Journal of Gastroenterology | March 20, 2023 | Volume: 118 | Issue: 7 | Pages: 1282-1284

10.14309/ajg.0000000000002254 | PMID 36940436 Get It

INTRODUCTION: Use of the electronic health record (EHR) has become increasingly widespread. Higher EHR burden is associated with burnout, but this has not been specifically investigated among gastroenterology (GI) providers. METHODS: We retrospectively collected measures of EHR use for outpatient GI providers during a 6-month period. We compared metrics across provider sex, subspecialty, and training (physicians vs nonphysician providers [NPPs]). RESULTS: Data collected represented more than 16,000 appointments from 41 providers across the Division of Gastroenterology and Hepatology. Inflammatory bowel disease (IBD) and hepatology specialists spent more time per appointment in the EHR, clinical review, and outside regular hours compared with other subspecialists. NPPs spent more EHR time than physicians. DISCUSSION: IBD and hepatology specialists and NPPs may have disproportionally high EHR burden. More work is needed to understand differences in provider workload to combat burnout.
CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation
Lozada, María E., Zhang, Ning , Yang, Ju Dong , Voss, Molly M., Prasai, Kritika , Amakye, Dominic , Harmsen, William S. , Chaudhary, Sushant , Bathe, Oliver F. , Therneau, Terry M. , Roberts, Lewis R. , Jin, Weidong , Wongjarupong, Nicha , Amakye, Dominic O , Roberts, Lewis R , Jin, Weidong , Yang, Ju Dong , Borad, Mitesh J. , Patel, Tushar , Gores, Gregory J.

American Journal of Gastroenterology | March 20, 2023 | Volume: 118 | Issue: 12 | Pages: 2173-2183

10.14309/ajg.0000000000002258 | PMID 36940423 Get It

INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is a primary liver malignancy with poor prognosis. Current prognostic methods are most accurate for patients with surgically resectable disease. However, a significant proportion of patients with iCCA are not surgical candidates. We aimed to develop a generalizable staging system based on clinical variables to determine prognosis of all patients with iCCA. METHODS: The derivation cohort included 436 patients with iCCA seen between 2000 and 2011. For external validation, 249 patients with iCCA seen from 2000 to 2014 were enrolled. Survival analysis was performed to identify prognostic predictors. All-cause mortality was the primary end point. RESULTS: Eastern Cooperative Oncology Group status, tumor number, tumor size, metastasis, albumin, and carbohydrate antigen 19-9 were incorporated into a 4-stage algorithm. Kaplan-Meier estimates for 1-year survival were 87.1% (95% confidence interval [CI] 76.1–99.7), 72.7% (95% CI 63.4–83.4), 48.0% (95% CI 41.2–56.0), and 16% (95% CI 11–23.5), respectively, for stages I, II, III, and IV. Univariate analysis yielded significant differences in risk of death for stages II (hazard ratio [HR] 1.71; 95% CI 1.0–2.8), III (HR 3.32; 95% CI 2.07–5.31), and IV (HR 7.44; 95% CI 4.61–12.01) compared with stage I (reference). Concordance indices showed the new staging system was superior to the TNM staging for predicting mortality in the derivation cohort, P < 0.0001. In the validation cohort, however, the difference between the 2 staging systems was not significant. DISCUSSION: The proposed independently validated staging system uses nonhistopathologic data to successfully stratify patients into 4 stages. This staging system has better prognostic accuracy compared with the TNM staging and can assist physicians and patients in treatment of iCCA.
Go with the Flow to Maximize Clot Ingestion
Brinjikji, Waleed , Wainwrights, John, Contrares, Mayra, Chesler, Naomi C.

The Arab Journal of Interventional Radiology | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0043-1763454 Get It

Percutaneous Transesophageal Gastric Catheters: A Single Institution Experience
Zaazoue, Karim Ahmed, Core, Jacob , Devcic, Zlatko , Frey, Gregory, Wallace, Alex , McKinney, J. Mark , Coltvet, Lisa Rotellini , Toskich, Beau , Ritchie, Charles , Zaazoue, Karim A. , Elboraey, Mohamed, Frey, G. , Wallace, Alex

The Arab Journal of Interventional Radiology | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0043-1763436 Get It

Structure-based design and characterization of Parkin-activating mutations
Stevens, Michael , Croteau, Nathalie , Eldeeb, Mohamed A. , Zeng, Zhi Wei , Toth, Rachel , Durcan, Thomas M. , Springer, Wolfdieter , Muqit, Miratul M. K. , Trempe, Jean‐François , Toth, Rachel , Springer, Wolfdieter , Fon, Edward A , Muqit, Miratul Mk , Trempe, Jean-François , Antico, Odetta

Life Science Alliance | March 20, 2023 | Volume: 6 | Issue: 6 | Pages: e202201419

10.26508/lsa.202201419 | PMID 36941054 Get It

Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth
Stoellinger, Heidi, Quiñones‐Hinojosa, Alfredo , De Araujo Farias, Virginea, Alexanian, Arshak R. , Stoellinger, Heidi Marie, Farias, Virgínea

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2698139/v1 | PMID 36993520 Get It

Abstract Glioblastomas (GBM), also known as glioblastoma multiforme, are the most aggressive type of brain cancers. Currently, there is no real treatment for GBM and thus there is a compelling need for new therapeutic strategies for such type of cancers. Recently, we demonstrated that specific combinations of epigenetic modifiers significantly affect the metabolism and proliferation rate of two most aggressive GBM cell lines D54 and U-87. Importantly, these combinations exhibited minimal effect on normal stem cells growth. In this study we demonstrated that the combinations of modulators of histone and DNA covalent modifying enzymes that synergistically suppress D54 and U87 cell lines growth, also impair the viability of a patient freshly-derived GBM stem cell line. These data suggest that epigenetic modifiers alone or in specific combinations exhibit cytotoxic effect on established and low passage patient derived GB cell lines and thus could be a promising therapeutic approach for such type of brain cancers.
JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders
Ambrus-Aikelin, Geza, Takeda, Katsuyuki , Joetham, Anthony, Lazić, Miloš , Povero, Davide , Santini, Angelina M., Pranadinata, Rama F., Johnson, Casey D. , McGeough, Matthew D., Beasley, Federico C., Stansfield, Ryan, McBride, Christopher, Trzoss, Lynnie, Hoffman, Hal M. , Feldstein, Ariel E., Stafford, Jeffrey A., Veal, James M., Gelfand, Erwin W. , Stansfield, Ryan K., Bain, Gretchen

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2652913/v1 Get It

Abstract The NLRP3 inflammasome is an intracellular, multiprotein complex that promotes the auto-catalytic activation of caspase-1 and the subsequent maturation and secretion of the pro-inflammatory cytokines, IL-1β and IL-18. Persistent activation of the NLRP3 inflammasome has been implicated in the pathophysiology of a number of inflammatory and autoimmune diseases, including neuroinflammation, cardiovascular disease, non-alcoholic steatohepatitis, lupus nephritis and severe asthma. Here we describe the preclinical profile of JT002, a novel small molecule inhibitor of the NLRP3 inflammasome. JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis, an inflammatory form of cell death triggered by active caspase-1. JT002 demonstrated in vivo target engagement at therapeutically relevant concentrations when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic endpoints in a model of Muckle-Wells syndrome (MWS). In two distinct models of neutrophilic airway inflammation, JT002 treatment significantly reduced airway hyperresponsiveness and airway neutrophilia. These results provide a rationale for the therapeutic targeting of the NLRP3 inflammasome in severe asthma and point to the use of JT002 in a variety of inflammatory disorders.
Robotic bronchoscopy: potential in diagnosing and treating lung cancer
Duke, Jennifer D. , Reisenauer, Janani

Expert Review of Respiratory Medicine | March 20, 2023 | Volume: 17 | Issue: 3 | Pages: 213-221

10.1080/17476348.2023.2192929 | PMID 36939545 Get It